Edwards Lifesciences Co. (NYSE:EW) Shares Bought by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC boosted its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 137.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 121,386 shares of the medical research company's stock after purchasing an additional 70,201 shares during the quarter. Schonfeld Strategic Advisors LLC's holdings in Edwards Lifesciences were worth $8,986,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the stock. Prosperity Consulting Group LLC lifted its holdings in shares of Edwards Lifesciences by 3.6% in the 4th quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock worth $289,000 after purchasing an additional 134 shares in the last quarter. Abacus Planning Group Inc. increased its stake in Edwards Lifesciences by 0.3% in the 4th quarter. Abacus Planning Group Inc. now owns 40,207 shares of the medical research company's stock valued at $2,977,000 after buying an additional 140 shares during the last quarter. Bowman & Co S.C. lifted its position in shares of Edwards Lifesciences by 1.2% during the 4th quarter. Bowman & Co S.C. now owns 12,487 shares of the medical research company's stock worth $924,000 after buying an additional 148 shares in the last quarter. Moors & Cabot Inc. boosted its position in Edwards Lifesciences by 0.3% in the fourth quarter. Moors & Cabot Inc. now owns 54,589 shares of the medical research company's stock worth $4,041,000 after purchasing an additional 152 shares during the last quarter. Finally, Quadrant Capital Group LLC grew its stake in Edwards Lifesciences by 3.1% in the 4th quarter. Quadrant Capital Group LLC now owns 5,180 shares of the medical research company's stock valued at $383,000 after purchasing an additional 156 shares during the period. 79.46% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Edwards Lifesciences news, Director Steven R. Loranger sold 5,739 shares of the company's stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $76.42, for a total transaction of $438,574.38. Following the transaction, the director now owns 60,372 shares in the company, valued at approximately $4,613,628.24. This represents a 8.68 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $67.96, for a total value of $645,620.00. Following the sale, the vice president now directly owns 46,936 shares of the company's stock, valued at approximately $3,189,770.56. This represents a 16.83 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,853 shares of company stock worth $5,163,062. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Trading Down 0.2 %

NYSE:EW traded down $0.18 during midday trading on Tuesday, hitting $74.93. The stock had a trading volume of 549,877 shares, compared to its average volume of 5,001,557. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The stock has a 50-day moving average of $71.23 and a 200 day moving average of $71.39. The company has a market capitalization of $44.05 billion, a price-to-earnings ratio of 10.76, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. The business had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same quarter last year, the firm posted $0.66 EPS. The company's revenue for the quarter was up 6.2% on a year-over-year basis. As a group, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current year.

Analyst Ratings Changes

EW has been the subject of a number of analyst reports. Royal Bank of Canada restated an "outperform" rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 12th. Evercore ISI dropped their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research report on Wednesday, February 12th. Canaccord Genuity Group raised their price target on Edwards Lifesciences from $71.00 to $75.00 and gave the stock a "hold" rating in a research note on Friday, April 25th. Piper Sandler raised Edwards Lifesciences from a "neutral" rating to an "overweight" rating and increased their target price for the stock from $73.00 to $80.00 in a research report on Thursday, April 24th. Finally, Wolfe Research downgraded Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences currently has an average rating of "Hold" and a consensus target price of $79.45.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.